Brain cancer boost: radioactive tile added to standard therapy in new trial
NCT ID NCT05342883
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether adding a special radiation tile (GammaTile) during brain surgery, followed by standard chemotherapy and radiation, is safe and feasible for people with newly diagnosed glioblastoma. About 61 participants will receive the tile implant at the time of tumor removal, then start standard chemoradiation within 21–35 days. The goal is to see if this combination can improve local tumor control without delaying standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GammaTile (cesium-131 brachytherapy device) and temozolomide
What this could lead to
If successful, this approach could improve local control of glioblastoma and potentially extend survival when added to standard treatment.
What could go wrong
This is a small, single-arm pilot study focused on feasibility and safety, not yet designed to prove efficacy. Adding radiation may increase side effects without clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advent Health Orlando
Orlando, Florida, 32803, United States
-
Brown University Health
Providence, Rhode Island, 02906, United States
-
ECU Health Medical Center - Vidant
Greenville, North Carolina, 27834, United States
-
Florida Health Sciences Center, Inc. d/b/a Tampa General Hospital
Tampa, Florida, 33606, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
HonorHeath Scottsdale Osborn Medical Center
Scottsdale, Arizona, 85251, United States
-
Indiana University Office of Clinical Research
Indianapolis, Indiana, 46202, United States
-
Keck Medicine of USC
Los Angeles, California, 90033, United States
-
Kettering Medical Center
Kettering, Ohio, 45429, United States
-
Piedmont Healthcare
Atlanta, Georgia, 30309, United States
-
RUSH University
Chicago, Illinois, 60607, United States
-
St. Louis University Hospital Center
St Louis, Missouri, 63110, United States
-
UC Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
UTHealth Houston | Memorial Hermann Health System
Houston, Texas, 77030, United States
-
University of Kansas Hospital
Kansas City, Kansas, 66016, United States
-
University of Minnesota
Minneapolis, Minnesota, 55485, United States